Federal judge blocks Kennedy's vaccine schedule overhaul, offering clarity for practices

A federal judge has temporarily halted the Trump administration's sweeping changes to the nation's childhood vaccine recommendations, delivering a ruling that brings short-term operational relief to physician practices navigating months of conflicting guidance.

U.S. District Judge Brian Murphy of Boston issued the ruling Monday in AAP et al. v. Kennedy et al., a lawsuit brought by the American Academy of Pediatrics and several other medical organizations. In January, Kennedy and the CDC had reduced the number of diseases covered by routine vaccines from 18 to 11, dropping universal recommendations for hepatitis A, hepatitis B, RSV, dengue and two forms of bacterial meningitis. Those vaccines were reclassified as appropriate only for high-risk patients or following shared clinical decision-making discussions with families.

For practices with pediatric or primary care patient panels, the policy shift had created a practical burden. The AAP, the AMA and more than a dozen other professional organizations had declined to adopt the federal changes and continued recommending the full set of immunizations, leaving physicians to counsel families navigating competing schedules. Murphy found the government had "bypassed" the Advisory Committee on Immunization Practices when revising the schedule, disregarding the committee's technical expertise.

The ruling also put on hold Kennedy's reconstitution of ACIP, the expert panel that has informed U.S. vaccine policy since 1964. Kennedy had fired all 17 members of ACIP in June and replaced them with his own appointees, many of whom are critical of vaccines. Murphy suspended the appointments of 13 of those members and stayed all votes they had taken, including the removal of the universal hepatitis B birth-dose recommendation and the narrowing of the combined MMRV vaccine guidance.

David H. Aizuss, MD, board chair of the American Medical Association, said the ruling was a win for evidence-based practice. "Today's ruling is an important step toward protecting the health of Americans, particularly children," Aizuss said. "Vaccines are one of the safest and most effective tools in medicine, and strong, science-based immunization policies save lives." The AMA joined an amicus brief in the case and was among more than 200 organizations that publicly opposed the schedule changes.

For practice administrators, the ruling effectively restores the pre-January 2026 vaccine schedule as the operative federal framework while litigation continues. The injunction also overturns the May 2025 secretarial directive on COVID-19 vaccine recommendations and reverses the downgraded hepatitis B recommendations from the December 2025 ACIP meeting. Practices can now align protocols with a single consistent standard rather than triangulating between federal guidance and specialty society schedules.

Insurance coverage had been a particular concern. AHIP, whose member plans cover more than 200 million Americans, had committed to covering all ACIP-recommended immunizations as of Sept. 1, 2025, without cost-sharing through the end of 2026. But experts have cautioned that federal programs including Vaccines for Children, Medicaid and Medicare Part D rely on ACIP recommendations to set no-cost coverage, and future policy shifts could affect reimbursement.

The hold is temporary. HHS has signaled it will appeal, with department spokesman Andrew Nixon saying the agency "looks forward to this judge's decision being overturned." The stay remains in place pending either a trial or a decision for summary judgment. Aizuss said the AMA would stay engaged: "The American Medical Association will continue to stand firmly with physicians, scientists, and public health experts to ensure vaccine recommendations remain grounded in the best available medical evidence and focused on protecting patients."

Practice administrators should continue monitoring the case, but the ruling offers a period of clearer, more stable guidance while the legal process plays out.